A Randomised, Placebo-controlled, Double-blind, Multicentre Efficacy and Safety Study of LJPC-501 in Paediatric Patients > 2 to 17 Years of Age with Catecholamine-Resistant Hypotension Associated with Distributive Shock
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Angiotensin II (Primary)
- Indications Hypotension
- Focus Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 19 Jul 2019 This trial has been completed in Estonia , according to European Clinical Trials Database.
- 30 May 2019 This trial has been discontinued in Lithuania, according to European Clinical Trials Database.
- 04 Jul 2018 Status changed from not stated to recruiting.